Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression
Shen Dongxing, Zhu Longyu, Zhang Jun, Kong Deyou, Liu Zhikun · 2026
Read Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression by Shen Dongxing, Zhu Longyu, Zhang Jun, Kong Deyou, Liu Zhikun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13327874.txt.
Description
Shen Dongxing and colleagues assess focused radiation for brain spread of HER2-positive breast cancer in a 2026 hospital review. Kinase inhibitor drugs help many such patients, but the brain can still worsen at a few spots. The review covered 40 patients treated with stereotactic radiotherapy for limited brain progression between January 2020 and January 2025.
Median time without brain progression after radiation was 6.4 months, and overall survival came to a median of 9.5 months at a median follow-up of 10.7 months across the group. Patients whose scans had been stable before progression fared better, at 7.9 months against 5.5 months for those already progressing. Severe side effects included diarrhea and anemia at 20 percent each.
Catalog record
| CREATOR | Shen Dongxing, Zhu Longyu, Zhang Jun, Kong Deyou, Liu Zhikun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23538 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |